Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLH

NCT04842019 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

X-linked Hypophosphatemia (XLH)

Interventions

DRUG: KRN23

Sponsor

Kyowa Kirin Co., Ltd.